Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sionna Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sionna Therapeutics's regulatory disclosures and financial reporting.
Sionna Therapeutics, Inc. reported topline results from two cystic fibrosis programs and outlined strategic changes. The Phase 2a PreciSION CF proof-of-concept trial of SION-719, added to Trikafta in people with cystic fibrosis, did not achieve the key activity endpoint of sweat chloride reduction, and the company is not advancing SION-719 as an add-on to standard of care. Potential confounders in this trial are being evaluated to guide next steps for the SION-451 dual combination program, which has completed a Phase 1 healthy volunteer trial with dual combinations involving SION-2222 and SION-109. Sionna ended Q2 with approximately $268.3 million in cash, cash equivalents, and marketable securities and plans to take actions to preserve capital while assessing future development plans.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on cystic fibrosis, developing NBD1 stabilizers and complementary CFTR modulators. It reported a net loss of $56.7 million for the six months ended June 30, 2026, compared with $34.6 million a year earlier, as R&D and G&A spending increased with pipeline advancement.
Research and development expenses rose to $40.8 million and general and administrative costs to $21.2 million. Cash, cash equivalents and marketable securities totaled $268.3 million, which management expects will fund operations into 2028. Sionna also has an unused $250.0 million at-the-market equity facility and is progressing a Phase 2a trial of SION-719 and a Phase 1 dual-combination trial of SION-451 with complementary modulators.
Sionna Therapeutics, Inc. reported second quarter 2026 results and provided an update on its cystic fibrosis pipeline. Research and development expenses were $21.9 million and general and administrative expenses were $10.6 million, resulting in a net loss of $29.9 million, or $0.66 per share for the quarter.
The company reported $268.3 million in cash, cash equivalents and marketable securities as of June 30, 2026 and expects this cash position to fund operations into 2028. Pipeline highlights include the PreciSION CF Phase 2a proof-of-concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care and a Phase 1 dual combination trial of SION-451 with SION-2222 and SION-109, both on track for topline data in summer 2026. Sionna also presented encore clinical and nonclinical data on its NBD1 stabilizers at major cystic fibrosis conferences.
Sionna Therapeutics director-affiliated fund reports share sale. An entity associated with director Peter A. Thompson, OrbiMed Private Investments VIII, LP, sold 85,918 shares of Sionna Therapeutics common stock in an open-market transaction at $44.86 per share pursuant to a Rule 10b5-1 plan. Following the sale, the entity continues to hold 2,469,959 shares indirectly. OrbiMed-related entities and the reporting person may be deemed to have beneficial ownership through control relationships but each disclaims beneficial ownership beyond any pecuniary interest.
ORBIMED ADVISORS LLC and OrbiMed Capital GP VIII LLC, reporting as directors of Sionna Therapeutics, Inc., reported an indirect open‑market sale of common stock. On July 7, 2026, an affiliated investment fund sold 85,918 shares of Sionna common stock at $44.86 per share.
The sold shares are held of record by OrbiMed Private Investments VIII, LP, for which OrbiMed Capital GP VIII LLC is the general partner and OrbiMed Advisors LLC is the managing member. Following this sale, indirect holdings reported for the OrbiMed entities totaled 2,469,959 shares of Sionna common stock. The sale was executed under a Rule 10b5-1 trading plan, and the reporting persons disclaim beneficial ownership of the securities except to the extent of any pecuniary interest.
Sionna Therapeutics, Inc. Chief Legal Officer Jennifer Fitzpatrick reported an exercise-and-sell transaction involving company common stock. She exercised options to acquire 10,250 shares of common stock at an exercise price of $6.11 per share and sold the same 10,250 shares in an open-market transaction at a weighted-average price of $43.5963 per share. The filing states that this sale was automatically executed under a Rule 10b5-1 trading plan adopted on June 5, 2025. Following these transactions, the report shows she holds no shares of common stock directly. The underlying option grant vested 25% on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments, subject to continued service.
Sionna Therapeutics director-affiliated fund reports planned share sale. OrbiMed Private Investments VIII LP, an entity associated with director Peter A. Thompson, sold 115,844 shares of Sionna Therapeutics common stock in an open-market transaction at $45.50 per share under a Rule 10b5-1 trading plan. Following this sale, 2,555,877 shares of Sionna common stock are reported as indirectly held, with OrbiMed-related entities and the reporting person disclaiming beneficial ownership beyond any pecuniary interest.
OrbiMed-affiliated entities reported an open-market sale of Sionna Therapeutics stock under a pre-arranged trading plan. An entity associated with OrbiMed sold 115,844 shares of Sionna Therapeutics, Inc. common stock at a price of $45.50 per share pursuant to a Rule 10b5-1 plan. After this transaction, the OrbiMed-related holder continues to own 2,555,877 shares indirectly through OrbiMed Private Investments VIII, LP, reflecting a large remaining position. OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC may be deemed to share voting and investment power over these shares, but they each disclaim beneficial ownership beyond any pecuniary interest.
Sionna Therapeutics director Laurie Stelzer received a grant of non-qualified stock options covering 17,340 shares of common stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting, subject to her continued service. Following this grant, Stelzer holds options for 17,340 underlying shares directly, reflecting a routine equity-based compensation award rather than an open-market share purchase or sale.